Increased Postprandial Nonesterified Fatty Acid Appearance and Oxidation in Type 2 Diabetes Is Not Fully Established in Offspring of Diabetic Subjects by Normand-Lauzière, François et al.
Increased Postprandial Nonesterified Fatty Acid
Appearance and Oxidation in Type 2 Diabetes Is Not
Fully Established in Offspring of Diabetic Subjects
Franc ¸ois Normand-Lauzie `re
1, Fre ´de ´rique Frisch
1,S e ´bastien M. Labbe ´
1, Patrick Bherer
1,2, Rene ´ Gagnon
2,
Stephen C. Cunnane
3, Andre ´ C. Carpentier
1*
1Division of Endocrinology, Department of Medicine, Universite ´ de Sherbrooke, Sherbrooke, Que ´bec, Canada, 2Division of Genetics, Department of Pediatrics, Universite ´
de Sherbrooke, Sherbrooke, Que ´bec, Canada, 3Research Center on Aging, Sherbrooke, Que ´bec, Canada
Abstract
Background: It has been proposed that abnormal postprandial plasma nonesterified fatty acid (NEFA) metabolism may
participate in the development of tissue lipotoxicity and type 2 diabetes (T2D). We previously found that non-diabetic
offspring of two parents with T2D display increased plasma NEFA appearance and oxidation rates during intravenous
administration of a fat emulsion. However, it is currently unknown whether plasma NEFA appearance and oxidation are
abnormal during the postprandial state in these subjects at high-risk of developing T2D.
Methodology: Palmitate appearance and oxidation rates and glycerol appearance rate were determined in eleven healthy
offspring of two parents with T2D (positive family history, FH+), 13 healthy subjects without first-degree relatives with T2D
(FH-) and 12 subjects with T2D at fasting, during normoglycemic hyperinsulinemic clamp and during continuous oral intake
of a standard liquid meal to achieve steady postprandial NEFA and triacylglycerols (TG) without and with insulin infusion to
maintain similar glycemia in all three groups.
Principal Findings: Plasma palmitate appearance and oxidation were higher at fasting and during the clamp conditions in
the T2D group (all P,0.05). In the postprandial state, palmitate appearance, oxidative and non oxidative rates were all
elevated in T2D (all P,0.05) but not in FH+. Both T2D and FH+ displayed elevated postprandial TG vs. FH- (P,0.001). Acute
correction of hyperglycemia during the postprandial state did not affect these group differences. Increased waist
circumference and BMI were positively associated with elevated postprandial plasma palmitate appearance and oxidation.
Conclusions/Significance: Postprandial plasma NEFA intolerance observed in subjects with T2D is not fully established in
non-diabetic offspring of both parents with T2D, despite the presence of increased postprandial plasma TG in the later.
Elevated postprandial plasma NEFA appearance and oxidation in T2D is observed despite acute correction of the
exaggerated glycemic excursion in this group.
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Introduction
Offspring of two parents with type 2 diabetes (T2D) have a very
high lifetime risk of developing overt T2D [1]. One of their earliest
identifiable metabolic defects is increased postprandial levels of
plasma triacylglycerols (TG) and blunted early postprandial
lowering of plasma nonesterified fatty acids (NEFA) [2]. In
subjects at increased risk of developing T2D, impaired postpran-
dial reduction of NEFA by insulin may contribute to the
development of insulin resistance and impaired b-cell function
through increased exposure of non-adipose tissues to fatty acids
[3].
We have recently shown that in offspring of both parents with
T2D (FH+), plasma NEFA appearance and oxidation rate both
increase significantly during intravenous infusion of heparin +
Intralipid [4]. We showed that this « NEFA intolerance » was
linked to defective non-oxidative plasma NEFA metabolism, i.e.
possibly reduced adipose tissue NEFA storage, and was unlikely to
involve a defect in insulin-mediated suppression of intracellular
lipolysis. We also found that lower plasma adiponectin is
associated with increased NEFA appearance during intravenous
lipid infusion in humans [5], which supports the concept of a
connection between adipose tissue dysfunction and increased
NEFA flux to non-adipose tissues during intravenous fat
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e10956administration. More recently, we demonstrated that NEFA
intolerance to intravenous lipid infusion is closely associated with
a lipid-induced decrease in insulin sensitivity and b-cell function in
vivo in overweight and obese individuals [6], thus linking NEFA
intolerance to enhanced susceptibility to lipotoxicity in humans.
The aim of the present study was to determine whether NEFA
intolerance is present during the postprandial state, e.g. during a
more physiological oral fat loading, in offspring of two parents
with T2D (FH+) compared to healthy subjects without a family
history of T2D (FH-), and to subjects with established but well-
controlled T2D. Our hypothesis was that increased postprandial
NEFA appearance and oxidation may be an early feature in non-
diabetic subjects at high risk of developing T2D.
Materials and Methods
Ethics statement
Informed written consent was obtained from all participants in
accordance with the Declaration of Helsinki and the protocol
received approval from the Human Ethics Committee of the Centre
hospitalier universitaire de Sherbrooke.
Subjects
Thirty-six non smoking subjects aged between 18 and 60 y old,
participated in these metabolic studies (see Table 1). Eleven
healthy FH+ subjects (defined as two biological parents with onset
of diabetes after age 30 that did not necessitate insulin therapy at
the time of diagnosis), thirteen healthy FH2 subjects and twelve
subjects with established T2D participated in the studies. Based on
a 75 g oral glucose tolerance test [7], none of the FH+ and FH-
subjects had diabetes nor were they taking any chronic medication
other than stable thyroid hormone replacement therapy. They had
no current medical condition known to affect lipid levels or insulin
sensitivity, and had no known cardiovascular disease. T2D
subjects were well-controlled (HbA1c,7.5%) on diet alone and/
or with only one oral hypoglycaemic agent (sulfonylurea,
metformin, repaglinide, nateglinide or acarbose). The women
who participated were pre-menopausal and the studies were
conducted during the follicular phase of their menstrual cycle.
Experimental Protocols
All subjects participated in three metabolic protocols performed
3 to 4 wk apart in random order (Figure 1). The subjects were
instructed to follow an isocaloric diet (0% alcohol, 15% protein,
30% fat and 55% carbohydrates) for 48 h before each metabolic
protocol. Subjects treated with an oral glucose lowering agent were
instructed to stop their medication 2 days before the protocols and
to monitor closely their blood glucose. On arrival, body weight,
height and waist circumference were measured and lean body
mass was determined by electrical bioimpedance (Hydra ECF/
ICF, Xitron Technologies, San Diego, CA). An intravenous
catheter was placed in one forearm for infusions, and another was
placed in a retrograde fashion in the contralateral arm maintained
in a heating box (,55uC) for blood sampling.
The first protocol was designed to measure NEFA and glycerol
metabolism at fasting for the first 2 h and during a normoglycemic
(,5.5 to 6.0 mmol/l) hyperinsulinemic clamp for the last two hours,
as previously described [8] (referred to as fasting and clamp
conditions throughout). The second and third protocols were
designed toassessNEFA and glycerol metabolismduring continuous
oral intake of a standard liquid meal designed to achieve steady state
postprandial NEFA and TG levels over 6 h [9] (referred to as PP
condition throughout). The fat drink was prepared by sonication of
soybean oil (54 g/l), safflower oil (54 g/l), dried non-fat milk
(263 g/l), egg phospholipids (0.18 g/l) and water with the
addition of chocolate syrup (202 g/l) and sugar (15 g/l) to provide
2465 kcal/l, 39% as fat, 16% as proteins, 45% as carbohydrates. Its
fatty acid composition was similar to the composition of Intralipid,
an intravenous fat emulsion that we have used in our previous
studies: palmitate 10%, oleate 32%, linoleate 46%, a-linolenate 8%,
and stearate 4% [9]. The oral intake of the drink corresponded to
28.4 ml every 15 min for a total of 1680 kcal over 6 h. During the
third protocol, plasma glucose was clamped at ,5.5 to 6.0 mmol/l
over the last 3 h of the 6 h postprandial period using a variable
dextrose 20% intravenous infusion adjusted every 5 min according
to plasma glucose (Beckman Glucose Analyzer II, Beckman
Instruments Corporation, Fullerton, CA) during intravenous
insulin infusion (primed 0.8 mU/kg continuous 1.2 mU/kg/min
infusion of Novolin Toronto, Mississauga, ON). This protocol was
performed to control for any potential effect of the difference in
plasma glucose on postprandial fatty acid metabolism and oxidation
[10] (referred to as PP/clamp condition throughout).
From time 0 min in the fasting protocol and from time 240 min
in both postprandial protocols, a constant infusion of [U-
13C]-K
palmitate (0.01 mmol/kg/min in 100 ml 25% human serum
albumin; Cambridge Isotopes Laboratories Inc., Andover, MA)
and a primed (1.6 mmol/kg) continuous (0.11 mmol/kg/min)
infusion of [1,1,2,3,3-
2H5]-glycerol (Cambridge Isotopes Labora-
tories Inc.) were administered [8], preceded by an intravenous
bolus of [1-
13C]-NaHCO3 (1.2 mmol/kg, Cambridge Isotopes
Laboratories Inc.) to prime the bicarbonate pool [11]. The choice
of a palmitate tracer in our experimental protocols was based on
the following: 1) palmitate, oleate, and linoleate are the most
prevalent NEFA in human plasma and have similar clearance
Table 1. Characteristics of the participants.
Groups P*
FH2 (n=13) FH+ (n=11) T2D (n=12) Group Group difference
Age (yr) 28.263.1 37.162.9 52.162.6 ,0.001 T2D?others
Gender (M:F) 7:6 2:9 5:7 0.22 -
BMI (kg/m
2) 24.861.3 27.361.8 34.262.0 0.001 T2D?others
LBM (kg) 55.764.2 46.763.9 54.864.1 0.26 -
Waist (cm) 81.563.5 88.963.5 105.764.2 ,0.001 T2D?others
*P values are from one-way ANOVAs with Scheffe’s post-hoc test for difference between groups or from Fisher’s exact test. BMI: body mass index; FH-: no family history
of type 2 diabetes; FH+: offspring of both parents with type 2 diabetes; LBM: lean body mass; T2D: subjects with type 2 diabetes.
doi:10.1371/journal.pone.0010956.t001
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measure total NEFA turnover in humans after oral fat intake
[13,14]; and 3) NEFA appearance determined with palmitate
tracer alone predicts very well NEFA appearance determined
using combined palmitate and linoleate tracers during intravenous
infusion of heparin + Intralipid in humans (r=0.90, P,0.001)
[15]. All tracers were pre-tested for sterility and non-pyrogenicity.
The protocols started with 30 min bed rest, after which blood
samplesweretakenat10-minintervalsatbaselineandduringthelast
30 minofeachofthefourexperimentalphases:1)endofthefirsttwo
hours of the first protocol=fasting (Fasting); 2) end of the last two
hours of the first protocol=normoglycemic hyperinsulinemic clamp
(Clamp); 3) end of the 6-hour postprandial protocol=PP; and 4) end
of the 6-hour postprandial protocol with insulin infusion=PP/
clamp. Blood was collected in tubes containing Na2EDTA and
Orlistat (30 mg/ml, Roche, Mississauga, Canada) to prevent in vitro
triacylglycerol lipolysis. After a 10 min equilibration, VO2 and
VCO2 were measured by indirect calorimetry (Vmax29n, Sensor-
medics) during a 30 min baseline period and during the last 30 min
of each four experimental phases to determine net carbohydrate (net
CHOox) and net fatty acid oxidation (net FATox) [16]. Expiratory
gases were collected at baseline and at 10-min intervals into 10 ml
evacuated glass tubes (Exetainers, Labco Ltd, High Wycombe,
Buckinghamshire, UK) [8].
Laboratory assays
Glucose, insulin, total NEFA and TG were measured as
described [4]. Plasma glycerol and plasma [1,1,2,3,3-
2H5]-glycerol
enrichment were measured by GC/MS whereas plasma palmitate,
linoleate, oleate, and [U-
13C]-palmitate enrichment were mea-
sured by LC/MS as previously described [8]. The intra-assay and
inter-assay coefficients of variation were less than 15% for all of
these assays. Breath
13CO2/
12CO2 ratio was determined using a
gas isotope ratio mass spectrometer [8] (Sercon Ltd, Crewe,
Cheshire, UK).
Calculations
Insulin sensitivity index (SI) was calculated from the normogly-
cemic hyperinsulinemic clamp data [17]. Plasma palmitate
appearance and clearance rates and NEFA appearance were
calculated as previously described [8,15]. Plasma glycerol
appearance rate was determined from plasma glycerol M+5
enrichment over baseline and from tracer infusion rate [18].
Fractional plasma palmitate oxidation was determined [19] with
correction for the fractional acetate recovery [8]. Individual
assessment of the fractional acetate recovery with an acetate tracer
was not possible in the present study due to its complex design, but
we found from our previous studies [4,8] that this factor can be
estimated using a linear function of time of tracer infusion
(y=0.0563+0.001359t, R
2=0.99, where t is duration of tracer
infusion in minutes). This relationship was not significantly
affected by intravenous insulin infusion (not shown). Plasma
palmitate oxidation rate was then calculated by multiplying
Foxpalmitate by Rapalmitate [8]. Palmitate non-oxidative metabolism
was calculated by subtracting palmitate oxidation from palmitate
appearance rate.
Figure 1. Experimental protocols. Each participant underwent three experimental protocols. The first protocol consisted, first, of a two-hour
fasting experimental phase (time 0 to 120 min) followed by a two-hour normoglycemic hyperinsulinemic clamp (time 120 to 240 min) with
determination of plasma glycerol and NEFA metabolism using stable isotopic tracers. The second protocol (postprandial or PP protocol) consisted in
a 6-hour continuous oral intake of a standard liquid meal with determination of steady-state postprandial glycerol and NEFA metabolism using stable
isotopic tracers. The third protocol (postprandial with exogenous insulin infusion or PP+INS protocol) was identical to the second protocol with the
exception of intravenous insulin and dextrose infusion in the last 3 hours of the postprandial experiment to maintain normoglycemia (,5.5 to
6.0 mmol/l) in all participants.
doi:10.1371/journal.pone.0010956.g001
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Data are expressed as mean 6 SEM unless stated otherwise.
Gender distribution between the groups was compared by Fisher’s
exact test whereas other group characteristic were compared by
ANOVA with Scheffe’s post-hoc test. Data at baseline and during
the four experimental phases (Fasting, Clamp, PP and PP/clamp)
were averaged and metabolic rates were expressed in absolute
terms (mmol/min). Two-way ANOVAs for repeated measures
were performed with experimental phases, groups and interaction
as the dependent variables and with Scheffe’s post-hoc test to
determine the significance of group differences. These analyses
were performed without and with adjustment for age, BMI,
gender, waist circumference or SI by ANCOVA since subjects
with T2D in our study were older and more obese than the other
two groups and because gender distribution was not strictly
matched between groups. We also examined the relationship
between postprandial glycerol and NEFA metabolic rates and age,
gender, BMI, lean body mass, waist circumference, REE, glycemia
and insulin sensitivity index using univariate Pearson correlations.
When multiple significant correlations were found, multivariate
models were built to examine whether these variables remained
independently associated with postprandial glycerol and NEFA
metabolic rates. A two-tailed P value,0.05 was considered
significant. All analyses were performed with the SAS software
for Windows, version 9.1.3 (SAS Institute Inc, Cary, NC).
Results
Basal fasting plasma metabolites and insulin (Table 2 -see
also expanded version of the table in the supporting
material ‘Table S1’)
Fasting plasma glucose, insulin, TG and glycerol were signifi-
cantly higher in T2D vs. the other two groups (P,0.001), whereas
fasting plasma NEFA were not significantly different between the
three groups of participants. Fasting plasma glucose, insulin, NEFA,
TG, glycerol, and free plasma palmitate, oleate and linoleate were
also similar between all three experimental protocols.
Plasma glucose, insulin, NEFA and TG (Figures 2, 3 and 4)
Plasma glucose at fasting was significantly higher in T2D vs. FH-
and FH+ (P,0.001) (Figure 2A), but was similar in all three groups
during the normoglycemic hyperinsulinemic clamp. Plasma glucose
throughout protocol PP (Figure 2B) was significantly higher in
T2D (P,0.001), but was similar in all three groups after time
180 min in protocol PP/clamp (Figure 2C). Plasma insulin was
higherat fastingand duringPP inT2D(P,0.001)butwas similar in
the three groups during the clamp and PP/clamp (data not shown).
Plasma NEFA were not significantly different between the three
groups at fasting and during the clamp (Figure 3A), but were
significantly higher in T2D (P,0.001) during the PP and PP/clamp
protocols (Figure 3B and 3C). Plasma TG were higher in T2D vs.
the two other groups (P,0.001) at fasting and during the clamp
(Figure 4A) and in the PP and PP/clamp protocols (Figure 4B
and 4C). Plasma TG were higher in FH+ vs. FH- (P,0.001) only
during the PP and PP/clamp protocols. Group differences in insulin
and NEFA wereabolished after adjustingfor waist circumferenceor
BMI but not after adjusting for gender, age or lean body mass.
Adjustment for these factors did not abolish group differences in
plasma TG during the postprandial state.
Metabolic rates during fasting and the normoglycemic
hyperinsulinemic clamp (Table 3 and Figure 5 –see also
expanded version of the table in the supporting material
‘Table S2’)
Net CHOox was lower whereas net FATox, plasma glycerol
and individual plasma NEFA were all higher in T2D vs. FH- and
Table 2. Basal fasting metabolites and insulin levels.
Protocols P*
Groups Fasting and clamp protocol PP PP/clamp Protocol Group Group difference
Glucose (mmol/l) FH2 5.060.2 4.860.1 4.760.1 0.37 ,0.001 T2D?others
FH+ 5.060.1 5.060.1 4.860.1
T2D 7.060.4 6.560.4 7.060.3
Insulin (pmol/l) FH2 66685 8 655 5 65 0.57 ,0.001 T2D?others
FH+ 81687 5 669 0 610
T2D 123623 127627 166644
NEFA (mmol/l) FH2 397644 433640 454643 0.88 0.09 -
FH+ 471685 392653 374655
T2D 514646 543672 476675
TG (mmol/l) FH2 0.9560.12 0.8460.12 0.8060.10 0.38 ,0.001 T2D?others
FH+ 1.2560.22 1.1260.15 1.1260.17
T2D 1.6960.15 1.5460.28 1.4260.16
Glycerol (mmol/l) FH2 72657 2 657 5 65 0.95 0.001 T2D?others
FH+ 75611 73610 7167
T2D 94679 8 610 91611
*P values are from two-way ANOVAs with Scheffe’s post-hoc test for difference between groups. Differences between groups remained significant after adjustment for
lean body weight, gender or age. However, adjustment for BMI or waist circumference abolished group differences in insulin, triacylglycerol and glycerol levels, but not
the other group differences.
FH2: no family history of type 2 diabetes; FH+: offspring of both parents with type 2 diabetes; LBM: lean body mass; NEFA: nonesterified fatty acids; PP: postprandial
experimental protocol; PP/clamp: postprandial with insulin infusion experimental protocol; T2D: subjects with type 2 diabetes; TG: triacylglycerol.
doi:10.1371/journal.pone.0010956.t002
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age, BMI or waist circumference, but not for gender, abolished
group differences for plasma glycerol. Glucose infusion rate and SI
tended to be lower in T2D vs. FH- and FH+ subjects (glucose
infusion rate: 31.065.0, 48.365.5 and 45.566.7 mmol/kg lean
body mass/min, respectively, P=0.08; SI: 6.961.8, 11.161.2 and
9.761.7610
4 dl/kg lean body mass/min per mU/l, respectively,
P=0.17). Glycerol appearance was higher in T2D vs. FH+ and
palmitate appearance and oxidation rates were higher in T2D vs.
FH-. Exogenous insulin infusion significantly increased net
CHOox and reduced net FATox, plasma glycerol and appearance
rate, individual plasma NEFA and palmitate appearance,
oxidation and non oxidative disposal (all P,0.01). These effects
of insulin infusion were similar in the three groups (all interaction
P.0.05).
Metabolic rates during the postprandial state without
and with normalization of plasma glucose with
exogenous insulin infusion (Table 4 and figure 6 –see
also expanded version of the table in the supporting
material ‘Table S3’)
Net CHOox tended to be lower and net FATox tended to be
higher in T2D vs. the other groups during the postprandial state.
Glycerol level and appearance rate, palmitate, oleate and linoleate
free plasma levels and palmitate appearance (Figure 6A),
oxidation (Figure 6B), non oxidative disposal (Figure 6C) and
NEFA appearance (Figure 6D) were significantly higher in T2D
(all P,0.05). Adjustment for waist circumference, but not for age,
gender, BMI or SI, abolished these group differences. Exogenous
insulin infusion significantly reduced total NEFA, palmitate, oleate
and linoleate levels but did not change net CHOox and FATox,
plasma glycerol and appearance rate, or palmitate appearance and
oxidation and non oxidative disposal. These effects of insulin
infusion were similar in the three groups (all interaction P.0.05).
Determinants of plasma glycerol and NEFA metabolism
during the postprandial state (Table 5 and Figure 7)
Glycerol appearance rate was positively correlated with BMI
and REE, and negatively correlated with SI. In multivariate
analyses, BMI remained significantly and positively associated
with glycerol appearance rate. Palmitate appearance rate was
positively correlated with BMI, waist circumference (shown in
Figure 7A), postprandial glycemia, and REE. Palmitate oxidation
rate was positively associated with age, BMI (shown in Figure 7B),
waist circumference, postprandial glycemia, and REE. Palmitate
non oxidative metabolic rate was positively associated with BMI,
waist circumference and REE. In multivariate models, waist
circumference remained independently related to postprandial
plasma palmitate appearance and non oxidative metabolism
whereas BMI, REE and lean weight (partial R
2=0.20, 0.07 and
0.07, respectively) remained independently related to palmitate
oxidative rate. Net FATox was positively correlated with lean body
mass, waist circumference, BMI and REE. REE remained
Figure 2. Plasma glucose over time during the experimental
protocols. Plasma glucose levels during the fasting and clamp
protocol (A), the postprandial protocol (B) and the postprandial
protocol with exogenous insulin infusion (C) in healthy subjects
without first-degree family history of type 2 diabetes (open circles,
continuous lines), in offspring of both parents with type 2 diabetes
(closed circles, dashed lines) and in subjects with established type 2
diabetes (closed triangles, dotted lines). Data are mean 6 SEM.
doi:10.1371/journal.pone.0010956.g002
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multivariate analyses.
Discussion
To our knowledge, this is the first study to report postprandial
fatty acid metabolic rates using tracer techniques in FH+ subjects.
We report here that FH+, a population at very high lifetime risk of
developing T2D [1], do not display abnormal fasting or
postprandial glycerol and NEFA metabolism compared to FH-.
Plasma glycerol and NEFA metabolism were also similar between
FH+ and FH- during a normoglycemic hyperinsulinemic clamp.
FH+ participants in the present study had normal SI and were
only slightly older and overweight compared to FH- participants.
In accordance with previous studies [2], however, we found that
FH+ subjects display increased postprandial plasma TG compared
to FH- subjects, suggesting that postprandial abnormalities in TG
metabolism may occur earlier than postprandial abnormalities in
NEFA metabolism in the natural history of T2D. Other
investigators have shown that insulin-resistant offspring of parents
with T2D have impaired skeletal muscle oxidative metabolism
during fasting [20] associated with impaired muscle mitochondrial
substrate oxidation [21]. The FH+ participants in the present
study, in contrast, were not significantly insulin resistant compared
to the FH- participants. Another previous study reported unaltered
postprandial plasma NEFA levels after either a high carbohydrate
or a high fat meal in FH+ subjects [22]. The latter study reported
less postprandial reduction in RQ after the high fat meal in FH+
compared to FH- subjects, but did not report actual fatty acid
oxidation or plasma NEFA appearance rates. We did not observe
any difference in postprandial change in RQ between FH+ and
FH- participants (data not shown), but our standard meal
contained less fat (39% vs. 76% of energy content [22]).
In accordance with previous studies, we found that subjects with
already established T2D displayed increased postprandial plasma
NEFA and TG and increased palmitate appearance rate [13]. The
T2D participants in the present study were older and more obese
with large waist circumference compared to the FH- or FH+
groups. Waist circumference appeared to be a major determinant
of postprandial plasma palmitate appearance in our cohort of
participants, also in accordance with previous studies showing
increased postprandial plasma NEFA appearance in centrally
obese subjects [23]. We also demonstrated, for the first time to our
knowledge, that acute correction of hyperglycemia does not alter
the observed differences in postprandial plasma NEFA and
glycerol metabolism between T2D and non-diabetic individuals.
Increased postprandial appearance of plasma NEFA in T2D
was associated with an increase in both oxidative and non
oxidative palmitate metabolism. BMI was the principal determi-
nant of postprandial palmitate oxidation rate, whereas increased
waist circumference appeared to drive the increase in non
oxidative palmitate metabolism associated with T2D. We also
found a significant increase in net FATox using indirect
calorimetry both at fasting and in the postprandial state in
participants with T2D compared to FH- and FH+ groups, results
consistent with those reported from a large European cohort [24].
Figure 3. Plasma nonesterified fatty acids (NEFA) over time
during the experimental protocols. Plasma nonesterified fatty acid
levels during the fasting and clamp protocol (A), the postprandial
protocol (B) and the postprandial protocol with exogenous insulin
infusion (C) in healthy subjects without first-degree family history of
type 2 diabetes (open circles, continuous lines), in offspring of both
parents with type 2 diabetes (closed circles, dashed lines) and in
subjects with established type 2 diabetes (closed triangles, dotted
lines). Data are mean 6 SEM.
doi:10.1371/journal.pone.0010956.g003
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postprandial NEFA and net FATox. Our results demonstrate
using two independent methods that whole body postprandial fatty
acid oxidation is elevated in T2D in humans.
In contrast to our present findings, however, many studies have
shown reduced plasma palmitate oxidation rate in obese subjects
and in those with impaired glucose tolerance and T2D upon
stimulation of adipose tissue lipolysis with a beta-adrenergic
agonist or with physical activity [19,25,26], associated with
reduced plasma NEFA extraction and oxidation in skeletal muscle
[27,28]. In the latter in vivo studies, plasma NEFA and appearance
rate were similar or even lower in the obese or T2D subjects.
These discordant findings probably reflect both lower adipose
tissue and intramyocellular lipolysis and NEFA release in insulin
resistance [29–31], leading to reduced oxidative fatty acid
utilization. We found increased plasma palmitate appearance
and oxidation in T2D during the postprandial period and also
during fasting, although the later differences were significant only
between the T2D and FH- groups. Elevation of plasma NEFA
normally leads to increased net FATox in both obese and lean
men [32]. Recent studies in animal models of T2D have found
results that are similar than ours with regards to circulating fatty
acids (e.g. high after feeding) associated with evidence of
mitochondrial fatty acid overload [33]. Some investigators have
also recently challenged the presence of impaired mitochondrial
oxidative function in T2D and insulin resistant subjects [34–38].
The results of the present study also challenge the view that
impaired capacity for fatty acid oxidation occurs, at least at the
whole body level, in T2D or in pre-diabetic states.
The higher oxidative disposal of NEFA in T2D observed in the
present study is consistent with increased exposure to and
deposition of dietary fatty acids in the liver and skeletal muscle
in subjects with T2D [39]. Dietary fatty acids recycle into VLDL
within hours in healthy subjects [14,40,41]. Indeed, some
proportion of NEFA derived from intravascular TG lipolysis is
available in the systemic circulation during both fasting and in the
postprandial state [14,42,43]. Although we did not determine the
source of the increased NEFA appearance and oxidation rates in
T2D, we previously demonstrated that increased NEFA spillover
during intravenous fat loading at high insulin level does not result
from abnormal insulin-mediated suppression of intracellular
lipolysis in pre-diabetic individuals [4]. It is therefore likely that
enhanced postprandial NEFA appearance observed in T2D
originated from dietary fatty acids.
The steady state design of our postprandial study did not fully
reproduce physiological meal intake and, therefore, this may limit
our conclusions. For example, in a previous study, postprandial
plasma NEFA spillover was larger with discrete meal intake
compared to continuous enteral infusion [40]. Therefore, it is
possible that we did not detect subtle differences in postprandial
NEFA metabolism in the FH+ group. Indeed, in our previous
study using intravenous heparin + Intralipid infusion which
induces greater and more rapid onset of fat loading in the
circulation, we found significantly higher plasma NEFA and
palmitate appearance rate in FH+ vs. FH- subjects of similar age,
Figure 4. Plasma triacylglycerols (TG) over time during the
experimental protocols. Plasma triacylglycerol levels during the
fasting and clamp protocol (A), the postprandial protocol (B) and the
postprandial protocol with exogenous insulin infusion (C) in healthy
subjects without first-degree family history of type 2 diabetes (open
circles, continuous lines), in offspring of both parents with type 2
diabetes (closed circles, dashed lines) and in subjects with established
type 2 diabetes (closed triangles, dotted lines). Data are mean 6 SEM.
doi:10.1371/journal.pone.0010956.g004
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tation is the fact that FH+ had similar postprandial NEFA levels
and metabolic rates despite trend towards higher mean insulin
levels (see Table S3), suggesting some adipose tissue insulin
resistance in this group [44]. The design of the present study
nevertheless allowed detection of significant changes in postpran-
dial plasma NEFA metabolism in subjects with T2D. Although we
cannot conclude that FH+ subjects do not display any abnormal-
ities in postprandial NEFA metabolism, it is clear from our
findings that these abnormalities are mild or not fully established
compared to subjects with already established but well-controlled
T2D.
We have previously demonstrated that steady state plasma
NEFA levels and appearance are achieved within 90 minutes
during intravenous TG emulsion without and with insulin infusion
[15]. Nevertheless, postprandial circulating NEFA come from at
least two different sources during the postprandial state (e.g.,
adipose tissue lipolysis and circulating TG lipolysis), it is therefore
impossible to ascertain that both of these sources achieved steady
state during the experimental design of the present study. For this
reason, we opted for a 3-hour insulin infusion period during the
postprandial state to maximize the likelihood of achieving steady
state NEFA appearance from dietary fatty acids. Our study has
other limitations. First, it was impossible to determine fractional
acetate recovery in each individual and in all experimental
conditions. We used a time-dependent function determined in our
previous studies using intravenous heparin+Intralipid infusion
without and with insulin infusion to estimate fractional acetate
recovery. In support of this approach, another group recently
demonstrated that application of average acetate recovery during
the postprandial state leads to ,10% over or underestimation of
fatty acid oxidation [45]. In the latter study, it was shown that no
demographic or anthropometric characteristics significantly af-
fected acetate recovery. We therefore feel that our conclusions
regarding palmitate oxidative rates are valid. Furthermore, gender
distribution was not strictly matched between our groups of
participants. In addition to statistical adjustment for gender that
did not affect our conclusions, we also performed separate analyses
including only the female participants and found similar results
with regards to group differences (data not shown). Therefore, we
believe that gender mismatch did not affect our conclusions. Our
participants with T2D and to a lesser extent, FH+ participants,
also were more obese and older than FH- participants. Although
statistical adjustment for age did not generally affect group
differences, adjustment for waist circumference or BMI signifi-
cantly attenuated group differences in postprandial NEFA
metabolism. This suggests that differences in postprandial NEFA
metabolism may have been affected by varying degree of central
adiposity [23,46]. We did not measure visceral vs. subcutaneous
abdominal fat content in our participants and, therefore, we
cannot assess which central fat compartment is responsible for
these associations. An increase in subcutaneous abdominal adipose
Table 3. Metabolic rates at fasting without and with normoglycemic hyperinsulinemic clamp.
Experimental phases P*
Groups No clamp Clamp Protocol Group Protocol x group Group difference
CHOox (mmol/min) FH2 9416128 15486136 ,0.001 0.002 0.30 T2D?FH2
FH+ 7456130 13556155
T2D 6256159 8556124
FATox (mmol/min) FH2 254625 121615 ,0.001 ,0.001 0.52 T2D?others
FH+ 255631 138635
T2D 389640 319626
Glycerol (mmol/l) FH2 75643 6 63 ,0.001 0.003 0.78 T2D?others
FH+ 77673 5 66
T2D 100610 5268
Raglycerol (mmol/min) FH2 284633 141617 ,0.001 0.01 0.83 T2D?FH+
FH+ 235629 141633
T2D 368653 244661
Palmitate (mmol/l) FH2 145613 2166 ,0.001 0.007 0.18 T2D?FH2
FH+ 201622 2263
T2D 210624 52610
Oleate (mmol/l) FH2 206615 1962 ,0.001 0.008 0.42 T2D?FH2
FH+ 250624 3866
T2D 280629 5067
Linoleate (mmol/l) FH2 76661 7 62 ,0.001 0.005 0.13 T2D?FH2
FH+ 107692 0 62
T2D 107612 2963
*P values are from two-way ANOVAs with Scheffe’s post-hoc test for difference between groups. Differences between groups remained significant after adjustment for
gender. Adjustment for age or BMI abolished group difference in triacylglycerol and glycerol levels. Adjustment for waist circumference abolished group differences in
triacylglycerol, glycerol, glycerol appearance rate and oleate levels.
CHOox: net carbohydrate oxidation rate; FATox: net fatty acid oxidation rate; FH2: no family history of type 2 diabetes; FH+: offspring of both parents with type 2
diabetes; NEFA: nonesterified fatty acids; Raglycerol: glycerol appearance rate; T2D: subjects with type 2 diabetes; TG: triacylglycerol.
doi:10.1371/journal.pone.0010956.t003
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Plasma palmitate appearance (Rapalmitate – A), palmitate oxidative metabolism (Oxpalmitate – B), palmitate non oxidative metabolism (NonOxpalmitate –
C) and nonesterified fatty acid appearance (RaNEFA – D) were not significantly different between healthy subjects without first-degree family history of
type 2 diabetes (FH2 – white bars) and offspring of both parents with type 2 diabetes (FH+ – grey bars). Subjects with established type 2 diabetes
(T2D – black bars) had significantly higher Rapalmitate and Oxpalmitate than FH2.R a palmitate,O x palmitate, NonOxpalmitate and RaNEFA were all significantly
reduced during insulin clamp. * P,0.05 vs. FH2. Adjustment for age, waist circumference, BMI or insulin sensitivity, but not for gender, abolished
difference between groups. Data are mean 6 SEM.
doi:10.1371/journal.pone.0010956.g005
Figure 6. Plasma nonesterified fatty acid (NEFA) metabolism during the postprandial state without and with euglycemic
hyperinsulinemic clamp. Plasma palmitate appearance (Rapalmitate – A), palmitate oxidative metabolism (Oxpalmitate – B), palmitate non oxidative
metabolism (NonOxpalmitate – C) and nonesterified fatty acid appearance (RaNEFA – D) in healthy subjects without first-degree family history of type 2
diabetes (FH2 – white bars), offspring of both parents with type 2 diabetes (FH+ – grey bars) and subjects with established type 2 diabetes (T2D –
black bars). * P,0.05 vs. FH2. { P,0.05 vs. FH+. Adjustment for waist circumference, but not for age, gender, BMI or insulin sensitivity, abolished
difference between groups. Data are mean 6 SEM.
doi:10.1371/journal.pone.0010956.g006
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participants with T2D [23,46].
In conclusion, FH+ have increased postprandial plasma TG but
do not yet fully display the increased plasma NEFA appearance
and oxidation rates observed in subjects with established T2D.
These abnormalities in postprandial NEFA metabolism in T2D
are associated with the presence of abdominal obesity and are not
prevented by acute correction of hyperglycemia. Our results
Table 4. Metabolic rates during the postprandial state without and with normalization of glucose level with exogenous insulin
infusion.
Experimental phases P*
Groups PP PP/clamp Protocol Group Protocol x group Group difference
CHOox (mmol/min) FH2 17886252 18636218 0.26 0.77 0.86 -
FH+ 16806237 19776143
T2D 15776191 18016175
FATox (mmol/min) FH2 177634 175629 0.41 0.01 0.67 FH+?T2D
FH+ 161647 84638
T2D 266663 251649
Glycerol (mmol/l) FH2 61655 1 63 0.09 0.01 0.98 FH+?T2D
FH+ 58694 5 66
T2D 79611 69611
Raglycerol (mmol/min) FH2 230626 211631 0.54 0.006 0.95 T2D?others
FH+ 214646 177641
T2D 339660 329651
Palmitate (mmol/l) FH2 40610 2266 ,0.001 0.004 0.63 T2D?others
FH+ 49672 4 66
T2D 78613 4269
Oleate (mmol/l) FH2 43642 4 62 ,0.001 ,0.001 0.08 FH2?T2D
FH+ 71610 3364
T2D 96613 4367
Linoleate (mmol/l) FH2 65610 3565 ,0.001 0.05 0.90 -
FH+ 74683 9 65
T2D 95618 55610
*P values are from two-way ANOVAs with Scheffe’s post-hoc test for difference between groups. Adjustment for gender or insulin sensitivity index did not abolish any of
the group differences. Adjustment for age and BMI abolished group differences in glycerol level. Adjustment for waist circumference abolished group differences in
NEFA, palmitate, oleate, linoleate, glycerol levels and appearance rate, and in net fatty acid oxidation.
CHOox: net carbohydrate oxidation rate; FATox: net fatty acid oxidation rate; FH2: no family history of type 2 diabetes; FH+: offspring of both parents with type 2
diabetes; NEFA: nonesterified fatty acids; PP: postprandial experimental protocol; PP/clamp: postprandial with insulin infusion experimental protocol; Raglycerol: glycerol
appearance rate; T2D: subjects with type 2 diabetes; TG: triacylglycerol.
doi:10.1371/journal.pone.0010956.t004
Table 5. Univariate correlation between characteristics of the participants and postprandial glycerol and nonesterified fatty acid
metabolism.
Raglycerol Rapalmitate Oxpalmitate NOxpalmitate FATox
Age 0.05 (0.78) 0.29 (0.09) 0.44 (0.01) 0.22 (0.24) 0.21 (0.23)
BMI 0.54 (,0.001) 0.50 (0.002) 0.77 (,0.001) 0.46 (0.01) 0.37 (0.03)
LBM 0.23 (0.18) 0.27 (0.11) 0.22 (0.24) 0.15 (0.41) 0.44 (0.008)
Waist 0.32 (0.07) 0.52 (0.002) 0.63 (,0.001) 0.47 (0.01) 0.42 (0.02)
Glycemia 20.06 (0.74) 0.47 (0.005) 0.68 (,0.001) 0.32 (0.08) 0.30 (0.08)
SI 20.36 (0.03) 20.19 (0.27) 20.37 (0.04) 20.45 (0.01) 20.25 (0.14)
REE 0.36 (0.04) 0.41 (0.02) 0.44 (0.01) 0.45 (0.01) 0.55 (,0.001)
Pearson correlation coefficients (P values in parenthesis) are shown between metabolic variables expressed in mmol/min. BMI: body mass index; CHOox: net
carbohydrate oxidation rate; FATox: net fatty acid oxidation rate; LBM: lean body mass; NEFA: nonesterified fatty acids; nonOxpalmitate: palmitate non oxidative metabolic
rate; Oxpalmitate: palmitate oxidation rate; Raglycerol: glycerol appearance rate; RaNEFA: nonesterified fatty acid appearance rate; Rapalmitate: palmitate appearance rate; REE:
resting energy expenditure; SI: insulin sensitivity index.
doi:10.1371/journal.pone.0010956.t005
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occurs progressively over the natural history of T2D in association
with the development of abdominal obesity.
Supporting Information
Table S1 Expanded version of Table 2: Basal fasting metabolites
and insulin levels. *P values are from two-way ANOVAs with
Scheffe’s post-hoc test for difference between groups. Differences
between groups remained significant after adjustment for lean
body weight, gender or age. However, adjustment for BMI or
waist circumference abolished group differences in insulin,
triacylglycerol and glycerol levels, but not the other group
differences. CHOox: net carbohydrate oxidation rate; FATox:
net fatty acid oxidation rate; FH-: no family history of type 2
diabetes; FH+: offspring of both parents with type 2 diabetes;
NEFA: nonesterified fatty acids; T2D: subjects with type 2
diabetes; TG: triacylglycerol.
Found at: doi:10.1371/journal.pone.0010956.s001 (0.08 MB
DOC)
Table S2 Expanded version of Table 3: Metabolic rates at
fasting and during normoglycemic hyperinsulinemic clamp. *P
values are from two-way ANOVAs with Scheffe’s post-hoc test for
difference between groups. Differences between groups remained
significant after adjustment for gender. Adjustment for age
abolished group difference in triacylglycerol and glycerol levels
and in palmitate appearance rate. Adjustment for BMI abolished
group differences in triacylglycerol and glycerol levels and in
glycerol and palmitate appearance rates, and in palmitate
oxidation rate. Adjustment for waist circumference abolished
group differences in triacylglycerol, glycerol and oleate levels, in
glycerol and palmitate appearance rates and in palmitate
oxidation rate. CHOox: net carbohydrate oxidation rate; FATox:
net fatty acid oxidation rate; FH-: no family history of type 2
diabetes; FH+: offspring of both parents with type 2 diabetes;
Foxpalmitate: palmitate fractional oxidation rate; NEFA: nonester-
ified fatty acids; nonOxpalmitate: palmitate non oxidative metabolic
rate; Oxpalmitate: palmitate oxidation rate; Raglycerol: glycerol
appearance rate; RaNEFA: nonesterified fatty acid appearance
rate; Rapalmitate: palmitate appearance rate; REE: resting energy
expenditure; T2D: subjects with type 2 diabetes; TG: triacylgly-
cerol, TTR: tracer to tracee ratio.
Found at: doi:10.1371/journal.pone.0010956.s002 (0.13 MB
DOC)
Table S3 Expanded version of Table 4: Metabolic rates during
the postprandial state without and with normalization of glucose
level with exogenous insulin infusion. *P values are from two-way
ANOVAs with Scheffe’s post-hoc test for difference between
groups. Adjustment for gender or insulin sensitivity index did not
abolish any of the group differences. Adjustment for age abolished
group differences in glycerol level. Adjustment for BMI abolished
group differences in glycerol level and appearance rate. Adjust-
ment for waist circumference abolished group differences in
NEFA, palmitate, oleate, linoleate, glycerol levels, in net fatty acid
oxidation, in glycerol, palmitate and NEFA appearance rates and
in palmitate oxidative and non oxidative metabolic rates. CHOox:
net carbohydrate oxidation rate; FATox: net fatty acid oxidation
rate; FH-: no family history of type 2 diabetes; FH+: offspring of
both parents with type 2 diabetes; Foxpalmitate: palmitate fractional
oxidation rate; NEFA: nonesterified fatty acids; nonOxpalmitate:
palmitate non oxidative metabolic rate; Oxpalmitate: palmitate
oxidation rate; Raglycerol: glycerol appearance rate; RaNEFA:
nonesterified fatty acid appearance rate; Rapalmitate: palmitate
appearance rate; REE: resting energy expenditure; T2D: subjects
with type 2 diabetes; TG: triacylglycerol, TTR: tracer to tracee
ratio.
Found at: doi:10.1371/journal.pone.0010956.s003 (0.13 MB
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